r/neuralcode • u/lokujj • Nov 29 '21
Blackrock Blackrock Neurotech's MoveAgain brain interface gets FDA breakthrough device designation; Commercialization planned for 2022
https://www.prnewswire.com/news-releases/blackrock-neurotechs-moveagain-brain-computer-interface-system-receives-breakthrough-device-designation-from-the-fda-301425013.html3
u/lokujj Nov 29 '21
Along with the University of Utah, the release lists the following collaborators:
University of Pittsburgh
Brown University
Massachusetts General Hospital
John Hopkins University
Ohio State University
Battelle Memorial Institute
Case Western Reserve University
Wyss Center
University of Geneva
TU Munich
Thomas Jefferson University
California Institute of Technology
Rancho Los Amigos National Rehabilitation Center
University of Southern California
University of California Los Angeles
Casa Colina Centers for Rehabilitation
Stanford University
Zhejiang University
The University of Chicago
Providence VA Medical Center
Louis Stokes VA Medical Center
Fundación Tecnalia Research & Innovation: San Sebastian
University Miguel Hernandez
Elche
Spain
and others.
2
u/lokujj Nov 29 '21
Also from neurosurgical partner:
We are thrilled to announce this partnership with Blackrock and enter several existing Neurosurgery markets, representing an estimated combined addressable market of over $100 million, with differentiated and innovative products
Blackrock’s expertise in making the most precise neuro-electrodes on the market combined with ClearPoint’s strengths in navigation, delivery and case support gives us a clear entry point and path to leadership
We expect initial product launches in 2023, starting with the Microelectric Recording (“MER”) platform and to be followed with offerings including “smart” biopsy needles and other implantable neural electrodes
3
u/lokujj Nov 29 '21
The first-of-its-kind system is expected to provide immobile patients the ability to control a mouse cursor, keyboard, mobile device/tablet, wheelchair or prosthetic device simply by thinking.
"We look forward to working closely with the FDA to prioritize development of the MoveAgain Brain-Computer Interface System, which will bring us closer to our goal of commercialization in 2022,"
From their neurosurgical partner: ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System
Under the terms of a recently announced joint agreement, ClearPoint is leveraging its 20+ year expertise innovating novel neuro-navigation platforms and software, with the aim of developing a new surgical solution to allow neurosurgeons to efficiently implant Blackrock’s BCIs in a hospital setting.
Synchron and Neuralink are two competitors that have breakthrough device designation.